<DOC>
	<DOC>NCT01816854</DOC>
	<brief_summary>In this prospective study, a newly developed self-expanding nitinol stent is evaluated for the treatment of atherosclerotic lesions in the superficial femoral artery.</brief_summary>
	<brief_title>Endovascular Treatment of Atherosclerotic Lesions in the SFA Using the Sinus-superflex-635 Stent</brief_title>
	<detailed_description />
	<mesh_term>Heart Diseases</mesh_term>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<criteria>Patient must sign informed consent prior to the indexprocedure Patient must be older than 18 years Patient must be compliant with followup dates at 1 month and 12 months Patients with intermittent claudication (Rutherford 23) and critical limb ischemia (Rutherford 45) Target lesion is located in the superficial femoral artery (minimal 1 cm from origin of SFA and minimal 1 cm above the edge of the patella) Reference vessel diameter ≥4.5 and ≤6.5 mm (visual estimate) Patients with a TASC A, B or C lesion Diameter stenosis of target lesion &gt;50% or chronic occlusions Inflow arteries are free of hemodynamically significant obstruction (i.e. ≥50%) The popliteal artery (outflow) is free of hemodynamically significant obstruction (i.e. ≥50%) At least 1 patent belowtheknee vessel (anterior tibial artery, posterior tibial artery or peroneal artery) till the ankle confirmed by baseline angiography Patients with Rutherford 1 and 6 Patiens with Serum creatinine &gt; 2.0 mg/dL or renal dialysis Patient takes esomeprazole or omeprazole Patient is pregnant Patient suffers from acute limb ischemia defined as any sudden decrease in limb perfusion causing a potential threat to limb viability Target lesion cannot be crossed with a guidewire Target lesion is located in the popliteal artery Patients with a nickeltitanium allergy Patients with an aneurysm in the superficial femoral artery and popliteal artery Patients with a TASC D lesion Patients with a life expectancy &lt;1 year Patients with scheduled elective nonvascular procedures within 3 months after indexprocedure, vascular procedures are allowed within 3 months after indexprocedure if it is guaranteed that acetylic salicylic acid and clopidogrel intake is not interrupted Patients with previous bypass surgery in the SFA Patients with intolerance to antithrombotic medication (acetylic salicylic acid, clopidogrel, ticlopidine, glycoprotein IIb/IIIa inhibitors, direct thrombin inhibitors, etc) Patient has not been premedicated with acetylic salicylic acid (at least 80 mg/day) 2 hours before the indexprocedure Patient has not been premedicated with clopidogrel (600 mg/day) 2 hours before the indexprocedure</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2015</verification_date>
	<keyword>SFA,</keyword>
	<keyword>stent,</keyword>
	<keyword>endovascular</keyword>
	<keyword>Patient outcome</keyword>
</DOC>